COMPANY:

Personalis

"Personalis...announced it will continue its collaboration with AstraZeneca...to explore ultra-sensitive molecular residual disease (MRD) measurement, including clinically relevant and personalized variant tracking, for clinical research and drug development...As part of the collaboration, Personalis’ NeXT Personal assay for liquid biopsy will aim to provide ultra-sensitive measurement of MRD, on-treatment therapy resistance tracking, and better differentiation between responders and non-responders, as well as investigate the underlying mechanisms driving cancer."

"Personalis, Inc...announced a collaboration with UC San Francisco (UCSF) that will deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal cancer. The research efforts will use Personalis’ NeXT Personal™ assay to evaluate circulating tumor DNA (ctDNA)-based signatures associated with treatment response and adverse events in a cohort of late-stage colorectal cancer patients receiving capecitabine together with pembrolizumab and bevacizumab."

"Personalis, Inc...announced that the company will share data resulting from expanded features of its NeXT Platform® at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 8-12 in Boston, with three abstracts that highlight advanced R&D applications of next-generation sequencing (NGS) in immuno-oncology...The company will present the following posters at SITC2022, as well as with customers including the Parker Institute for Cancer Immunotherapy (Abstracts 559 and 587) and Geneos Therapeutics (Abstracts 691 and 692)."

"Personalis, Inc...has joined with Duke University and Olink Proteomics AB to form a research collaboration to study the effects of immunotherapy on advanced gastroesophageal cancer. Specifically, the collaboration will focus on identifying composite biomarkers—those that integrate multiple biological entities into a single readout—to help guide therapeutic decision making...Personalis’ NeXT Personal assay will be used to analyze circulating tumor DNA (ctDNA) collected from patients in order to profile and accurately track molecular residual disease (MRD) over the course of therapy."

"Personalis, Inc...announced...it has filed an amended complaint against Foresight Diagnostics. The amended complaint asserts a newly-issued patent in Personalis’ growing intellectual property portfolio relating to detection of molecular residual disease (MRD)...Personalis’ patent portfolio protects its groundbreaking work in whole genome sequencing to identify mutations that indicate the continued presence or recurrence of cancer with an unprecedented part-per-million sensitivity, which its recently-launched MRD solution, NeXT Personal, is uniquely designed to achieve."

"Personalis, Inc. has announced a collaboration with BC Cancer to deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal and pancreatic cancers. The research efforts will deploy Personalis’ NeXT Personal, which has demonstrated high sensitivity for detecting circulating tumor DNA (ctDNA) from a patient’s blood sample, to determine the best time to draw blood for ctDNA sampling for molecular residual disease (MRD) detection. MRD describes a very small number of cancer cells that remain in the body during or after treatment."

"Personalis, Inc...announced today that it filed a lawsuit against Foresight Diagnostics Inc. for infringement of Personalis’ U.S. Patent Nos. 10,450,611, 11,299,783, and 11,384,394. These patents are part of Personalis’ intellectual property portfolio in the field of whole genome-enabled, tumor-informed molecular residual disease (MRD) testing...NeXT Personal is purpose-built to accurately detect MRD in patient samples with low overall ctDNA, which is particularly important for cancers that have low shedding or low mutational burden, such as breast and prostate cancers, or soon after resection."

"Personalis, Inc...has added another patent family to its molecular residual disease (MRD)-related IP portfolio, with priority to January 2013. US Patent No. 11,384,394 describes the detection of MRD and recurrence by using whole genome sequencing of a patient’s tumor to identify variants for a personalized liquid biopsy assay...As with recently issued US Patent 11,299,783, the ‘394 patent covers many elements of Personalis’ NeXT PersonalTM platform, including that it describes a highly sensitive measurement of tumor burden with simultaneous tracking of up to thousands of tumor variants, both tumor-informed and prespecified, in a single panel design."

"Evaxion Biotech A/S...and Personalis....announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of Evaxion’s personalized cancer immunotherapy EVX-01. The study will combine EVX-01, a neoepitope-targeting immunotherapy based on Evaxion’s proprietary PIONEER^® AI technology, with KEYTRUDA^® (pembrolizumab) for the treatment of patients with metastatic melanoma."

"Personalis, Inc...announced the publication of its study titled, 'A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity,' in Nature Communications...This study demonstrates DASH’s ability to sensitively detect subclonal events in samples with low tumor purity, enabling comprehensive profiling of widespread HLA LOH across tumor types."

"Personalis, Inc...announced the issuance of a key US Patent related to its industry-leading minimal residual disease (MRD) and recurrence platform, NeXT Personal...The patent, US Patent No. 11,299,783, entitled 'Methods and Systems for Genetic Analysis,' was issued on April 12, 2022. The ‘783 patent claims novel methods for a partially personalized assay, combining both tumor-informed and prespecified (tumor naïve) content. Tumor-informed methods can provide high sensitivity for detection of MRD."

"Personalis, Inc...announced its co-authorship of a study with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to be presented during the American Association for Cancer Research Annual Meeting 2022 from April 8-13, 2022...'Working with Merck KGaA, Darmstadt, Germany, and leveraging the combination of transcriptome and exome-based data generated by the ImmunoID NeXT Platform®, we were able to explore promising, integrative approaches to complementing the previously demonstrated classification method for colorectal cancer'."

"Personalis, Inc...announced it is presenting new data in scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2022, which will be held in-person and online, April 8-13, 2022....The NeXT Liquid Biopsy platform monitors tumor variants and discovers novel mutations in the plasma, through analysis of tumor, normal and plasma samples from the same patient."

"Personalis, Inc...announced a strategic collaboration with the Moores Cancer Center at University of California San Diego Health, a National Cancer Institute-designated Comprehensive Cancer Center, to support clinical diagnostic testing in patients with advanced solid tumors and hematological malignancies. The collaboration will bring Personalis’ leading comprehensive genomic tumor profiling test to UC San Diego health care professionals and their cancer patients to help guide FDA-approved therapy decisions, as well as clinical trial treatment options."

"Personalis...announced the launch of NeXT Personal, a next-generation, tumor-informed liquid biopsy assay designed to detect and quantify molecular residual disease (MRD) and recurrence in patients previously diagnosed with cancer. NeXT Personal delivers industry-leading MRD sensitivity down to the 1 part-per-million range, an approximately 10- to 100-fold improvement over other available technologies. This enables earlier detection across a broader variety of cancers and stages, including typically challenging early stage, low mutational burden, and low-shedding cancers."

"Personalis, Inc...today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 12-14, including online poster presentations and online industry sponsored symposium...The company will showcase the Personalis NeXT Platform® which enables comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The NeXT Platform can be used to investigate the key tumor and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen."

"Personalis, Inc...announced the latest expansion of the Personalis NeXT Platform® adding several new features that are key to the understanding of the interactions between the tumor and the immune system and how they may influence a cancer patient’s response to therapy...The new and improved features include:...InfiltrateID™, a sophisticated analytics module that leverages the augmented gene expression data from the NeXT Transcriptome™ to detect the presence of eight immune cell populations within a tumor sample...RepertoireID™ now incorporates the characterization of the B-cell receptor repertoire, including the computing of isotype makeup, as a complement to the previously released T-cell receptor repertoire feature...SHERPA™, further enhancing the performance of Personalis’ leading pan-allelic neoantigen prediction algorithm..."

"Personalis, Inc...announced the issuance of two key US Patents related to its high-performance, exome-wide liquid biopsy platform, NeXT Liquid Biopsy...The first patent, US Patent No. 11,142,802, entitled 'Methods for Using Mosaicism in Nucleic Acids Sampled Distal to Their Origin', issued on October 12, 2021...The second patent, US Patent No. 11,155,867, entitled 'Methods and Systems for Genetic Analysis', issued on October 26, 2021."

"Mayo Clinic announced an agreement on Tuesday, Oct. 12 that will allow it to offer clinical-grade comprehensive cancer genomic sequencing to cancer patients who choose to participate. Test results will be available to patients and their treating health care providers to guide therapeutic decisions, advance cancer research, and support the development of new diagnostic tests and therapies for cancer treatment...Mayo Clinic Cancer Center, Mayo Clinic's Department of Laboratory Medicine and Pathology, and Mayo Clinic's Center for Individualized Medicine are collaborating with Personalis Inc...The test will provide a clinical report for each patient and comprehensive aggregated data that Mayo Clinic and Personalis will use to further develop this comprehensive diagnostic approach."

"Personalis, Inc...today announced that the company will present new data in scientific posters to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held online, April 10-15, 2021 and May 17-21, 2021. These abstracts showcase data from ImmunoID NeXT, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The ImmunoID NeXT Platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen."

"Personalis, Inc...today announced a collaboration with MapKure, LLC...to use a clinical trial assay (CTA) based on the Personalis® NeXT Platform...to support development of BGB-3245, an investigational next-generation B-RAF inhibitor, in patients with advanced or refractory solid tumors. As part of this collaboration MapKure will be working with Personalis to utilize the NeXT Platform as a confirmatory test for patients enrolled into MapKure’s Phase 1a/1b dose escalation and expansion clinical trial. Additionally, MapKure will benefit from the breadth of the NeXT Platform, which enables broad tumor immunogenomic profiling of the tumor and consolidates multiple biomarker assays into one, providing a multidimensional view of the tumor and its tumor microenvironment from a single sample, which will help MapKure understand if other biomarkers are clinically relevant to BGB-3245."

"Natera…and Personalis…announced that the two companies have entered into a partnership in the field of personalized oncology. The partnership will pair Personalis' NeXT tumor profiling and diagnostic products with Natera's personalized ctDNA platform Signatera™ for treatment monitoring and molecular residual disease (MRD) assessment…Under this non-exclusive agreement, Natera will validate the design of Signatera personalized ctDNA assays using matched tumor and normal exome sequence data from Personalis, and Natera will be responsible for commercialization."